6th Post-MASCC Meeting, 14th Belgian Symposium

Belgian Society of Medical Oncology (BSMO) and the Jules Bordet Institute,

Supportive care in cancer: Is there a model?

Florian SCOTTE MDPhD Département Interdisciplinaire d'Organisation des Parcours Patients (DIOPP)






Disclosures

- Consultant / Advisory Boards / Speaker : Sanofi, Roche, MSD, TEVA, Norgine, Tesaro, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, AMGEN, Pierre Fabre Oncologie, Vifor pharma, Arrow, Pfizer, BMS, Tilray.
- Associations: ASCO, ESMO, MASCC, AESCO, AFSOS.

What is Supportive Care



Supportive care is the prevention and management of the adverse effects of cancer and its treatment across the entire continuum of a patient's illness - including the enhancement of rehabilitation and survivorship



GUSTAVE ROUSSY




Designated Centers of Excellence in Supportive Care in Cancer

Certification Program


MASCC Application Form

- www.mascc.org
- Center Informations (radiation oncology, palliative care unit, etc)
- Clinical Activities
 - Supportive care organisations
 - Ressources
 - Multidisciplinary Approach
 - Logistics
- Research and Educational Features
- Adherence to international Guidelines
- Narrative Section
 - Description of the organisation
 - Practical management
 - Specificities

IS THERE ONE MODEL ...



GAP OF PERCEPTION



Lancet Oncology Commission

Integration of oncology and palliative care: a *Lancet Oncology* and Commission

Stein Kaasa*, Jon H Loge*, Matti Aapro, Tit Albreht, Rebecca Anderson, Eduardo Bruera, Cinzia Brunelli, Augusto Caraceni, Andrés Cervantes, David C Currow, Luc Deliens, Marie Fallon, Xavier Gómez-Batiste, Kjersti S Grotmol, Breffni Hannon, Dagny F Haugen, Irene J Higginson, Marianne J Hjermstad, David Hui, Karin Jordan, Geana P Kurita, Philip J Larkin, Guido Miccinesi, Friedemann Nauck, Rade Pribakovic, Gary Rodin, Per Sjøgren, Patrick Stone, Camilla Zimmermann, Tonje Lundeby

> Tumour-directed approach: main focus = treating the disease

Host-directed approach: focuses on the patient with the disease

Lancet Oncology Commission

Integration of oncology and palliative care: a *Lancet Oncology* and Commission

pod CrossMark

Stein Kaasa^{*}, Jon H Loge^{*}, Matti Aapro, Tit Albreht, Rebecca Anderson, Eduardo Bruera, Cinzia Brunelli, Augusto Caraceni, Andrés Cervantes, David C Currow, Luc Deliens, Marie Fallon, Xavier Gómez-Batiste, Kjersti S Grotmol, Breffni Hannon, Dagny F Haugen, Irene J Higginson, Marianne J Hjermstad, David Hui, Karin Jordan, Geana P Kurita, Philip J Larkin, Guido Miccinesi, Friedemann Nauck, Rade Pribakovic, Gary Rodin, Per Sjøgren, Patrick Stone, Camilla Zimmermann, Tonje Lundeby

> Tumour-directed approach: main focus = treating the disease

Systematic assessment Use of patient-reported outcomes Active patient involvement in the decisions. Host-directed approach: focuses on the patient with the disease

Better symptom control, Improved physical and mental health,

Better use of health-care resources

The Early Palliative Care Model


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer


Jennifer S. Temel, M.D., Joseph A. Greer, Ph.D., Alona Muzikansky, M.A., Emily R. Gallagher, R.N., Sonal Admane, M.B., B.S., M.P.H., Vicki A. Jackson, M.D., M.P.H., Constance M. Dahlin, A.P.N., Craig D. Blinderman, M.D., Juliet Jacobsen, M.D., William F. Pirl, M.D., M.P.H., J. Andrew Billings, M.D., and Thomas J. Lynch, M.D.

Early Palliative Care (EPC)



Global: 9.8 months (Cl95%; 7.9 - 11.7) (151 pts), **EPC: 11.6 months** (Cl 95%; 6.4 - 16.9) (77 pts) **SOC: 8.9 months** (Cl 95%; 6.3 -11.4) (74 pts)


Survival Predictive Risk : HR 1.70 (CI ; 95%; 1.14 to 2.54) (P = 0.01).




THERAPY KNOWLEDGE

Therapies Knowledge – Pediatric Experience

- Objectives: to compare the causes of death of pediatric cancer survivors
- Assessment of causes of late treatment-related deaths
- Hazard regression to evaluate the mortality of each treatment




Therapies Knowledge – Pediatric Experience




Treatment Progresses are also Safety Management Improvements

From Supportive Care to Cancer Toxicity Management

Therapies Knowledge – Innovative Therapies





Champiat S. et al. Annals of Oncology 27: 559–574, 2016 adapted from Weber, et al., Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology, 2012.




The ImmunoTOX multidisciplinary board, a descriptive study of collaborative management of immune-related adverse events.



Jean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, Audrey Simonaggio, Michael Collins, Eléonora De Martin, François-Xavier Danlos, Samy Ammari, Cécile Cauquil, Stéphane Ederty, Emmanuel Barreau, Rakiba Belkinir, Amandine Berdelou, Julien Lazarovici, Philippe Chanson, Hassan Izzedine, Andrei Seferian, Christine Le Pajolec, Capucine Baldini, Patricia Romano-Martin, Xavier Maniette, Caroline Robert, Benjamin Besse, Antoine Hollebecque, Andrea Varga, Salim Laghouati, Christine Mateus, Anne-Laure Volsin, Jean-Charles Soria, Christophe Massard, Aurélien Marabelle, Stéphane Champiat and Olivier Lambotte.

On behalf of the ImmunoTox board, Departement d'innovation Therapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saciay, Villejuif, France

Main objectives of the multidisciplinary iTOX committee



SUPPORTIVE THERAPIES



Monitoring Patient at Home: PROCHE program

PROCHE: PRogramm of Optimisation of ChemotHErapy administration


Objective : Anticipation of drug delivery and evaluation of the toxicity profile by a medical call center dedicated to the oncology unit

PROCHE Project :

- \checkmark
- \checkmark
- Optimises Day Hospital Improves Quality of Life Improves Safety Reduces Hospitalisation



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health



Scotté F. et al. Eur J Cancer 2013. Scotté F. Oncologist 2012.

PROCHE Program


PR ogramme d'O ptimisation du ircuit des himiothérapiCs

Period = 01.2009 – 02.2011

1037 pts = prospective inclusion
513 pts = standard of care cohort

Wait before treatment


Evolution of incidence Fatigue (A) and Pain (B)



Scotté F. et al. Eur J Cancer 2013. Scotté F. Oncologist 2012. Scotté F et al. Supportive Care Cancer 2014.

NURSE ASSESSMENT (patients' call) Before (2008:) / Under PROCHE (2009-14:)






Scotté F. et al. Supportive Care Cancer 2014

ESMO GUIDELINES

Risk Factors


- Treatment characteristics
- Age (elderly)
- Advanced disease,
- History of prior FN,
- No antibiotic prophylaxis or granulocyte colony-stimulating factor (G-CSF) use
- Mucositis,
- Poor performance status and/or
- Cardiovascular disease



ORGANISATIONS



Pre-Habilitation / Re-Habilitation New Standard of Care ?



Silver J. - MASCC® 2015 - Plenary Session 2

The story of Supportive Care in Cancer Unit Pompipou Paris


S

- 2005: Creation cros disciplinary meetings SCC
- 2010: Creation SCUPP- 4 beds/ 1 MD
- 2012: 1st resident
- 2013: Increase 8 beds; 1 Fellow
- 2015: 2nd resident
 - → Incomes: Montant remboursé AM potentiel = 1 632 600,98 €
 - → Physician workforce (PM) : 0,6 ETP PH 2 CCA 1 DES 2 DFASM
 - \rightarrow Nursing workforce ((PNM): 0,5 ETP cadre IDE AS

Year	2011	2012	2013	2014	2015
Number of Stays	158	192	244	326	357
DMS	10,2	8,31	8,3	8,9	7,7
Incomes reimbursed by Health System	750 896,96€				1 632 600,98 €



- Assessment in Oncology Unit
- Limit Emergency hospitalisation
- Anticipation
- Cross Disciplinary Expertise



Objectives

- Assessment in Oncology Unit
- Limit Emergency hospitalisation
- Anticipation
- Cross Disciplinary Expertise

Transversal Team	% pts
Dietetician	64 %
Speech Therapist	13 %
Pain	80 %
Physiotherapist	50 %
Psyhologist	42 %
Social Worker	35 %





• Limit Emergency Department

• Anticipated Management, Short Stay, Home -Home

SOURCE OF PATIENTS			DISCHARGE OF PATIENTS			
	2011	2015		2011	2015	
Home	59,4 %	1 78,4 %	Home	51,8 % ᅟ 🕇	68,3 %	
Emergency	17,7 %	1 5,5 %	Rehabilitation	17 %	10,3 %	
Rehabilitation	10,1 %	2,4 %	Other Dpt	12 %	5,1 %	
Other Dpt	11,3 %	12 %	Death	6,9 %	4 %	
Palliative Unit	1,2 %	0 %	Palliative Unit	12 %	10,3 %	

Objectives

Ambulatory Supportive Care

Initial

Physiotherapist Physical Activity Nutrition Psycho-oncology Social Worker Relaxation / CAM

PRE-HABILITATION

Toxicity

Physiotherapist
 Physical Activity
 Nutrition
 Psycho-oncology
 Social Worker
 Relaxation / CAM


(PER)-HABILITATION

RE-HABILITATION


Survivorship

Physiotherapist Physical Activity Nutrition Psycho-oncology Social Worker Relaxation / CAM

Patient Reported Outcomes The STAR Study




Monitoring Patients Improves: Survival



Overall Survival: 31,2 versus 26,0 months HR = 0.832; CI_{95} : 0.696-0.995; p = 0.03


Monitoring Patients Improves: Quality of Life



Basch EM et al., JAMA. 2017 Jul 11; 318(2): 197-198

MOOVCARE vers le remboursement du device: Survival Benefit in Lung Cancer (n=121)

Symptoms vs Scan Monitoring



DIGITAL MONITORING : CAPRI

Intervention combining Nurse Navigators (NNs) and a mobile application vs. standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): results of CAPRI, a single-center, randomized phase 3 trial.

<u>Olivier Mir</u>, Marie Ferrua, Aude Fourcade, Delphine <u>Mathivon</u>, Adeline <u>Duflot-Boukobza</u>, Sarah <u>Naomie</u> Dumont, Eric Baudin, Suzette <u>Delaloge</u>, David Malka, Laurence <u>Albiges</u>, Patricia <u>Pautier</u>, Caroline Robert, David <u>Planchard</u>, Stéphane de Botton, François Lemare, Marilene Guillet, Vanessa <u>Puglisi</u>, May Abbas, Mario Di Palma, Etienne <u>Minvielle</u>.

Gustave Roussy Cancer Institute, Villejuif, France



1

PRESENTED AT: 2020ASCO ANNUAL MEETING


ASCO20 Blides are the property of the aution; permission required for reuse.


PRESENTED BY: Olivier Mir, MD, PhD, MPH

GUSTAVE ROUSSY

CAPRI: DESIGN

Monocenter randomized phase 3 trial = NNs + mobile application vs. standard of care





Web/mobile application

- → Dashboard for NNs to manage patients' records
- ➔ Interface for other healthcare professionals
- Patients can record tracking data, contact nurses via secure messaging, view therapy and side effect information or store documents

METHOD

• Primary endpoint : Relative Dose Intensity (RDI) at 6 months

- Hypothesis : increase by 5% (85 => 90%)
- Sample size estimation: n = 1000 (bilateral test, $\alpha = 0.05$, power 80%)
- Stratification: treatment line, treatment type (chemotherapy vs. molecular targeted therapy)

Secondary endpoints :

- Adherence (Morisky questionnaire, electronic medication monitoring system)
- Grade 3-4 toxicity (NCI-CTCAE 4.03)
- Patients' experience (PACIC score: visit 6)
- Quality of life (EORTC QLQC30: visits 0, 3, 6)
- Use of supportive care resources
- Economic estimation of the use of healthcare resources
- ORR (RECIST 1.1), PFS and OS

Primary endpoint: relative dose-intensity

		CAPRI	CONTROL	Total	p-value
RDI	Missing	0	0	0	
(until end of study)	N	272	287	559	
	Mean (SD)	0.9344 (0.2590)	0.8943 (0.1914)	0.9138 (0.2275)	p = 0.0426
	95% CI	[0.9035 ; 0.9653]	[0.8720 ; 0.9165]	[0.8949 ; 0.9327]	
RDI	Missing	17 (6.3%)	22 (7.7%)	39 (7.0%)	
Adjusted on adherence (Morisky scale)	N	255	265	520	
	Mean (SD)	0.8417 (0.2632)	0.7998 (0.2090)	0.8204 (0.2378)	p = 0.0451
	95% CI	[0.8093 ; 0.8742]	[0.7745 ; 0.8251]	[0.7999 ; 0.8408]	

Grade 3-4 toxicity

		CAPRI	CONTROL	Total	p-value
	N	272	287	559	
At least one toxicity grade ≥ 3	No	197 (72.4%)	181 (63.1%)	378 (67.6%)	
At least one toxicity grade 2 5	Yes	75 (27.6%)	106 (36.9%)	181 (32.4%)	p = 0.02
Skin toxicities	No	262 (96.3%)	265 (92.3%)	527 (94.3%)	
Skin toxicities	Yes	10 (3.7%)	22 (7.7%)	32 (5.7%)	p = 0.04
Metabolic /nutritional	No	263 (96.7%)	266 (92.7%)	529 (94.6%)	
toxicities	Yes	9 (3.3%)	21 (7.3%)	30 (5.4%)	p = 0.04


Emergency visits

		CAPRI	CONTROL	Total	p-value
	N	272	287	559	
Patients with emergency hospitalizations	No	231 (84.9%)	224 (78.0%)	455 (81.4%)	p = 0.04
	Yes	41 (15.1%)	63 (22.0%)	104 (18.6%)	

Variable		CAPRI	CONTROL	Total	p-value
	N	272	287	559	
Use of supportive care	No	153 (56.3%)	186 (64.8%)	339 (60.6%)	
resources	Yes	119 (43.8%)	101 (35.2%)	220 (39.4%)	p = 0.04
Туре	Analgesia	10 (3.7%)	15 (5.2%)	25 (4.5%)	p = 0.38
	Palliative care	17 (6.3%)	15 (5.2%)	32 (5.7%)	p = 0.60
	Nutrition	39 (14.3%)	25 (8.7%)	64 (11.4%)	p = 0.04
	Psychologist	37 (13.6%)	41 (14.3%)	78 (14.0%)	p = 0.82
	Social worker	59 (21.7%)	31 (10.8%)	90 (16.1%)	p = 0.0005
	Other	14 (5.1%)	24 (8.4%)	38 (6.8%)	p = 0.13


Progression Free Survival

Overall Survival



COVID-19 Pandemic: CAPRI Covid App











41

Gustave Roussy Model







"Supportive care makes excellent cancer care possible"

Dorothy M.K. Keefe, past President of MASCC